Comparison of IORT (Radical and Boost Dose) and EBRT in Terms of Disease-Free Survival and Overall Survival according to Demographic, Pathologic, and Biological Factors in Patients with Breast Cancer
International Journal of Surgical Oncology · 16.04.2021 · 2021 · 1-9
DOI: 10.1155/2021/2476527 ↗Kurz gefasst
Klinische Studie in der Zeitschrift International Journal of Surgical Oncology, erschienen am 16.04.2021. Verfasst von Solmaz Hashemi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tabriz University of Medical Sciences, General Surgery Department, Tabriz, Iran. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The standard treatment for breast cancer is breast-conserving surgery (BCS) with radiotherapy. If external beam radiation therapy (EBRT) can be safely replaced with intraoperative radiotherapy (IORT), it will help patients to save their breast and to have equivocal or better results in DFS and overall survival (OS).
Methods
A total of 2022 patients with breast cancer treated during 6 years were enrolled in the current study. A total of 657, 376, and 989 patients received EBRT, radical, and boost dose by IORT, respectively, according to the IRIORT consensus protocol. The primary endpoint was recurrence and death. The secondary endpoint was the role of variables in recurrence and death.
Results
With a mean follow-up of 34.5 and 40.18 months for the IORT and EBRT groups, respectively, there was a significant difference in DFS between electron boost and X-ray boost groups ( P = 0.037 ) and the electron radical group compared with EBRT ( P = 0.025 ), but there was no significant difference between other boost and radical groups in DFS and OS.
Conclusions
IORT can be a preferred treatment modality because of its noninferior outcomes, and in some special conditions, it has superior outcomes compared to EBRT, particularly in delivering radical dose with IORT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Tabriz University of Medical Sciences, General Surgery Department, Tabriz, Iran.
- Cancer Research Center Shahid Beheshti, University of Medical Sciences, Tehran, Iran.
- Hamadan University of Medical Sciences, General Surgery Department, Hamadan, Iran.
- Shahid Beheshti University of Medical Sciences, Cancer Research Center, Tehran, Iran.
- Department of Medical Physics, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Solmaz Hashemi, Seyedmohammadreza Javadi, Mohammad Esmaeil Akbari, Hamidreza Mirzaei, Seied Rabi Mahdavi
Zitieren
APA
Hashemi, S., Javadi, S., Akbari, M. E., Mirzaei, H., & Mahdavi, S. R. (2021). Comparison of IORT (Radical and Boost Dose) and EBRT in Terms of Disease-Free Survival and Overall Survival according to Demographic, Pathologic, and Biological Factors in Patients with Breast Cancer. International Journal of Surgical Oncology, 2021, 1-9. https://doi.org/10.1155/2021/2476527
Vancouver
Hashemi S, Javadi S, Akbari ME, Mirzaei H, Mahdavi SR. Comparison of IORT (Radical and Boost Dose) and EBRT in Terms of Disease-Free Survival and Overall Survival according to Demographic, Pathologic, and Biological Factors in Patients with Breast Cancer. International Journal of Surgical Oncology. 2021;2021:1-9. doi:10.1155/2021/2476527
BibTeX
@article{Hashemi2021,
author = {Hashemi, Solmaz and Javadi, Seyedmohammadreza and Akbari, Mohammad Esmaeil and Mirzaei, Hamidreza and Mahdavi, Seied Rabi},
title = {Comparison of IORT (Radical and Boost Dose) and EBRT in Terms of Disease-Free Survival and Overall Survival according to Demographic, Pathologic, and Biological Factors in Patients with Breast Cancer},
journal = {International Journal of Surgical Oncology},
year = {2021},
volume = {2021},
pages = {1--9},
doi = {10.1155/2021/2476527}
}
EUVIMED